Daily Goal Setting to Increase Everyday Physical Activity and Promote Cognitive Health in Midlife
Mechanisms of Adherence to Light Intensity Physical Activity to Prevent Alzheimer's Disease and Related Dementias (ADRD)
Study Overview
Status
Intervention / Treatment
Detailed Description
The study is designed to examine the efficacy of a Fitbit-based, goal setting, mHealth intervention to increase light intensity physical activity. The study design is a 2-arm randomized controlled trial. Both groups will receive the underlying goal-setting intervention (adaptive daily step goals). The study involves 3 phases: a run-in ("calibration") phase, the intervention ("training") phase, and follow-up (1- and 12-months post-intervention).
To support goal maintenance our team has developed a Fitbit application designed to operate on the Fitbit Versa series watch as a 'clockface'. The application will first calibrate participants' average level of physical activity by recording daily step counts for a period of 14 days (calibration phase). After this period (and following a health education session) the application will begin delivering the underlying intervention to both treatment and control groups for a period of 1 month. The intervention is composed of daily step goals presented via the Fitbit clockface. Each day the application will suggest a daily step goal. The algorithm used to make these suggestions relies on the participant's own activity during the calibration period and is updated each day in study, ensuring all proposed step goals are within their existing repertoire. Follow-up assessments will be completed at 1- and 12-monts post-intervention.
Outcomes and moderators will be measured via activity monitors (the Fitbit application and activPals), surveys, and ecological momentary assessments (self-ratings and performance-based ambulatory cognitive assessments) conducted via the Mobile Monitoring of Cognitive Change ("M2C2") platform.
Some of the details of the intervention, algorithm, experimental manipulations, and outcomes have been omitted to preserve the scientific integrity of the study. These details will be added after the study is closed.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Milton S. Hershey Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria*:
- Between 30 and 70 years of age
- BMI ≥ 25
Exclusion Criteria*:
- Clinical diagnosis of ADRD or other neurodegenerative disease
- Health condition contraindicated for increased physical activity
- Medical conditions or medications that would prohibit participation in an exercise test (e.g., decompensated heart failure, severe aortic stenosis, uncontrolled arrhythmia, and acute coronary syndromes)
- Limitations in use of a smart phone (e.g., issues with manual dexterity or visual impairment)
- Inability to walk unassisted
- BMI > 50
- Plan to have surgery or other procedure over the next 12 months that could affect mobility or light intensity physical activity maintenance
- Concurrent participation in a weight loss, physical activity, or cognitive training trial
- Failure to comply with Run-in Period activity monitoring (<70% valid wear days for the Fitbit and activPal)
- Anyone who will not discontinue the use of their own personal smartwatch during the training period.
- Anyone who scores below 19 on the MoCA-B would not be randomized after the Run-in Calibration Period.
Note: The eligibility criteria are deliberately incomplete to preserve the scientific integrity of the study. These details will be added after study closure.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Control
Participants receive the adaptive daily step goal mHealth intervention
|
Daily step goals displayed by the study application
|
|
Experimental: Treatment
Participants receive the adaptive daily step goal mHealth intervention plus interim goal setting prompts each day
|
Daily step goals displayed by the study application
Short-term step goals
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Short-term adherence
Time Frame: 1-month follow-up
|
Average of 14-day step count totals collected via ActivPal monitors
|
1-month follow-up
|
|
Long-term adherence
Time Frame: 12-month follow-up
|
Average of 14-day step count totals collected via ActivPal monitors
|
12-month follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Self-Monitoring Behavior
Time Frame: Daily during intervention period
|
Number of times participant checks their step count progress per day
|
Daily during intervention period
|
|
Change in Cognitive Health (Processing Speed)
Time Frame: Change in mean performance between the 2-week calibration phase and 12-month follow-up
|
Change in performance on ambulatory cognitive assessments of processing speed (response time during the "Symbol Search" task).
This task is administered twice daily (2 "sessions" per day) throughout the 2-week, baseline "calibration phase" and twice daily throughout the 2-week, 12-month follow-up phase.
The outcome to be modeled is median response time to trials administered during each session.
Aggregation of data collected over these 2-week data collection periods will be model-based (in other words, all 'session' data will be modeled nested within phase, within persons).
|
Change in mean performance between the 2-week calibration phase and 12-month follow-up
|
|
Change in Cognitive Health (Working Memory Binding)
Time Frame: Change in mean performance between the 2-week calibration phase and 12-month follow-up
|
Change in performance on ambulatory cognitive assessments of working memory binding (corrected recognition rate during the "Color Shapes" task).
This task is administered twice daily (2 "sessions" per day) throughout the 2-week, baseline "calibration phase" and twice daily throughout the 2-week, 12-month follow-up phase.
The outcome to be modeled is corrected recognition rate (hit rate minus false alarm rate) for trials administered during each session.
Aggregation of data collected over these 2-week data collection periods will be model-based (in other words, all 'session' data will be modeled nested within phase, within persons).
|
Change in mean performance between the 2-week calibration phase and 12-month follow-up
|
|
Change in Self-Efficacy for light intensity physical activity
Time Frame: Change between pre-enrollment baseline survey and end of training phase (an average of 2 months)
|
Self-efficacy for exercise scale (adapted to light intensity physical activity; range 0-90 points; higher scores reflect better outcomes)
|
Change between pre-enrollment baseline survey and end of training phase (an average of 2 months)
|
|
Executive Control (Working Memory Capacity)
Time Frame: Twice daily during the final 2 weeks of the training phase
|
Performance on ambulatory cognitive assessments of working memory capacity (span score during the "Rotation Span" task).
This task is administered twice daily (2 "sessions" per day) during the last 2 weeks of the "training phase".
The outcome to be modeled is the total recalled arrows across the 3 trials assessed during each session.
Data will not be aggregated, but instead modeled as a time-varying covariate.
|
Twice daily during the final 2 weeks of the training phase
|
|
Executive Control (Inhibitory Control)
Time Frame: Twice daily during the final 2 weeks of the training phase
|
Performance on ambulatory cognitive assessments of inhibitory control (commission errors during the "Go/NoGo" task).
This task is administered twice daily (2 "sessions" per day) during the last 2 weeks of the "training phase".
The outcome to be modeled is the total commission errors across the trials assessed during each session.
Data will not be aggregated, but instead modeled as a time-varying covariate.
|
Twice daily during the final 2 weeks of the training phase
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jonathan G Hakun, PhD, Milton S. Hershey Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00022087
- R61AG078084 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.